Elevated renin activity and change in sleep apnea with primary

aldosteronism 2

1

3

8

13

15

24

26

27

28

29

30

31

- Yonekazu Kidawara, M.D., Ph.D. Manabu Kadoya, M.D., Ph.D. Masataka Igeta, 4
- Ph.D.² Miki Kakutani-Hatayama, M.D., Ph.D.¹ Akiko Morimoto, M.D., Ph.D.¹ Akio 5
- Miyoshi, M.D., Ph.D.¹ Akinori Kanzaki, M.D., Ph.D.¹ Kosuke Konishi, M.D., 6
- Ph.D.¹ Takashi Daimon, Ph.D.² and Hidenori Koyama M.D., Ph.D.¹ 7
- 9 ¹Department of Diabetes, Endocrinology and Clinical Immunology, School of
- Medicine, Hyogo Medical University, Nishinomiya, Hyogo, Japan 10
- ²Department of Biostatistics, School of Medicine, Hyogo Medical University, 11
- 12 Nishinomiya, Hyogo, Japan
- 14 **Short title:** Primary aldosteronism and sleep apnea
- Corresponding author: 16
- Manabu Kadoya, M.D., Ph.D. 17
- 18 Department of Diabetes, Endocrinology and Clinical Immunology, School of
- 19 Medicine, Hyogo Medical University
- 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan 20
- 21 Tel: +81 798 45 6473; Fax: +81 798 45 6443
- 22 Email: mkadoya@hyo-med.ac.ip
- 23 ORCID: 0009-0004-3541-5270
- Total words (excluding abstract and references): 2301 25

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

perpetuity.
All rights reserved. No reuse allowed without permission.

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

ABSTRACT Background: The prevalence of obstructive sleep apnea (OSA) is higher in patients with primary aldosteronism (PA), while elevated renin activity after treatment is associated with a lower risk of cardiovascular events. However, the association of PA with degree of OSA remains unclear and it is not known whether elevated renin activity in PA patients is associated with change in apnea condition. Methods: Cross-sectional relationships between PA (n=176) and degree of OSA classified by apnea-hypopnea index (AHI) with use of an apnomonitor were investigated, with the results compared with those obtained with non-PA patients (n=418). Additionally, the effects of elevated renin activity on change in AHI were prospectively examined in 45 patients with PA. **Results:** Patients with PA were found to be significantly associated with severe OSA even after adjustment for other clinical risk factors (odds ratio 2.08, 95% confidence interval 1.09-3.95, p = 0.025) as compared to those without PA. Furthermore, the logarithm of the renin activity after treatment and change in AHI before and after treatment were significantly negatively correlated, with Pearson's correlation coefficient (r = -0.364, p = 0.014). **Conclusions:** Severe OSA is more commonly seen in PA patients with hypertension as compared to patients without PA, and elevated renin activity may contribute to improvement of sleep apnea in patients with PA.

Keywords: primary aldosteronism, sleep apnea, AHI, renin activity

Introduction

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

Primary aldosteronism (PA) is recognized as one of the most common causes of secondary hypertension, and affected individuals have also been shown to have a higher risk for cardiovascular events and mortality independent of blood pressure level as compared to patients with essential hypertension (EH)¹⁻⁴. Obstructive sleep apnea (OSA), another well-known cause of hypertension, has also been found to contribute to increased risk of cardiovascular morbidity and mortality ⁵⁻⁷. In patients with PA, the prevalence of OSA has been reported to be as high as 60% to 80% 8. Additionally, those patients have a tendency for higher OSA prevalence as compared to patients without PA who are hypertension resistant 9. Another report regarding risk of PA showed that individuals with maintained suppression of renin activity had increased risk of cardiovascular events and death ¹⁰. Therefore, unsuppressed renin activity is now recognized as a therapeutic goal for PA patients, though it remains unclear whether elevated renin activity is associated with changes related to apnea. The present study was performed as a cross-sectional examination of the association of PA with

- degree of OSA and also prospectively investigated the effect of elevated renin
- 74 activity on sleep apnea.

Methods

75

76

77

90

Study design and participants

78 From October 2010 to November 2020, 1151 patients assessed for diagnosis of 79 PA and OSA were enrolled in the Hyogo Sleep Cardio-Autonomic 80 Atherosclerosis (HSCAA) study. Out of these, 781 were hypertensive patients 81 including those with PA. For the present study, those with autonomous cortisol 82 pheochromocytoma, hyperparathyroidism, secretion, primary estimated glomerular filtration rate (eGFR) <15 mL/min/1.73 m², or dialysis treatment were 83 84 excluded (n=128). Additionally, 59 with missing baseline data regarding 85 assessment of OSA were also excluded. Finally, 594 were enrolled, and divided 86 into the PA (n=176) and non-PA (n=418) groups. Of those with PA, 45 patients were simultaneously reassessment for renin activity and sleep apnea within five 87 88 years (Figure 1). HSCAA study, which has received approved by the institutional 89 ethical committee of Hyogo Medical University (approval No. 2351), was used

and informed written consent was obtained from each participant.

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

Plasma biochemical parameters Blood samples were obtained in the morning after an overnight fast and then quickly centrifuged to obtain plasma. Whole blood was used for hemoglobin A1c, EDTA plasma for glucose and lipids, and serum for other biochemical assays. Glucose measurements were performed using a glucose oxidase method and an enzymatic method was used to determine serum creatinine concentration. Estimated glomerular filtration rate in each patient was calculated using an equation for Japanese subjects, as follows: estimated glomerular filtration rate (mL/min per 1.73 m²)=194×age (years)^{-0.287}×S-creatinine^{-1.094} (if female,×0.739). Plasma renin activity (PRA) and plasma aldosterone concentration (PAC) were measured using an enzyme immunoassay with the patient at rest in a supine position for 30 minutes. Diagnosis of primary aldosteronism Patients were diagnosed with PA based on a PAC (pg/mL) to PRA (ng/mL/hour) ratio (ARR) ≥200 at screening and at least one positive result from confirmatory

tests for PA diagnosis (saline infusion test, captopril challenge test,

furosemide-upright test) at the time of admission, according to previously reported guidelines ^{11,12}.

Assessment of sleep apnea

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

To determine the presence of sleep apnea, an apnomonitor device (SAS-2100, Nihon Kohden, Tokyo, Japan; supplied by Teijin, Tokyo, Japan) was used to provide apnea-hypopnea index (AHI) values. Criteria presented in The American Academy of Sleep Medicine Manual for the Scoring of Sleep and Associated Events, version 2.1, were used for analysis of respiratory events, as follows. Apnea was defined when the amplitude ratio to normal breathing was ≤10% with air flow lasting ≥10 seconds, and hypopnea when the amplitude ratio to normal breathing was ≤70% with air flow lasting ≥10 seconds and associated with a 4% decrease in oxygen saturation. AHI was calculated as the average number of apnea and hypopnea episodes per hour. When the decrease was 3% or more per second or the sensor was disconnected, the result was considered an artifact and excluded from analysis. The degree of sleep apnea was classified based on AHI values as none (0 to <5), mild (5 to <15), moderate (15 to <30), or severe (≥30) 13.

Statistical analyses

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

For comparisons of mean and median values of continuous variables for the baseline clinical characteristics between PA status (PA and non-PA), and also suppressed renin activity status in patients with PA (remained suppressed and unsuppressed), Welch's t-test or the Mann-Whitney U-test was used. Fisher's exact test was used for categorical variables. Multivariable logistic regression analysis was used to calculate odds ratio (OR) and 95% confidence interval (CI) values for the associations of degree of OSA with PA as compared to the non-PA group adjusting for clinical factors, including potential causal factors for sleep apnea, i.e., age, male gender, BMI, systolic BP, HbA1c, and renal function. In addition, a Pearson's correlation coefficient was calculated to evaluate the association between the change of AHI and elevation of the renin activity in PA patients. The logarithmic transformation was performed to the renin activity for a normal approximation. All statistical analyses were performed with EZR, version 1.61 (Saitama Medical Center, Jichi Medical University, Saitama, Japan) and SAS software version 9.4 (SAS Institute Inc., Cary, NC, USA). All reported P values are two-sided and considered to be statistically significant at <0.05

without adjustment for multiplicity.

Results

Baseline clinical characteristics

The baseline characteristics of the present patients after dividing into the PA and non-PA groups are shown in **Table 1**. The distribution of degree of sleep apnea in those with PA was as follows: normal (AHI <5), 26.7%; mild (AHI 5 to <15), 38.6%; moderate (AHI 15 to <30), 18.8%; and severe (AHI ≥30), 15.9%. Patients with PA exhibited higher levels of systolic BP, diastolic BP, and plasma aldosterone concentration, lower levels of fasting plasma glucose, HbA1c, and plasma renin activity, and lower prevalence of diabetes and dyslipidemia, as compared to the non-PA group.

The baseline clinical characteristics of the patients classified by degree of OSA are presented in **Table 2**. Comparisons were also made between patients classified according to degree of OSA and those without OSA. There were no clinically significant differences in regard to smoking, diastolic BP, LDL-cholesterol, PRA, PAC, or use of anti-hypertensive drugs such as

calcium-channel blocker and diuretic agent between patients with OSA regardless of severity as compared to those without OSA. Patients with OSA showed higher levels of BMI, systolic BP, FPG, and HbA1c, and a higher prevalence for male gender and diabetes, and lower level of eGFR as compared to patients without OSA. Those with mild or moderate OSA were older than those without OSA. As compared to patients without OSA, those with moderate or severe OSA had lower levels of HDL, higher levels of TG, and a higher prevalence of dyslipidemia. Users of α blocker anti-hypertensive drugs were more frequently noted among patients with severe OSA as compared to those without OSA. Furthermore, the prevalence of PA tended to be higher in patients with severe OSA, though the difference was not significant as compared to patients classified with other levels of OSA.

Relationship of PA with degree of OSA

177 Results of multivariable logistic analysis performed to examine the associations
178 of PA with each level of OSA as compared to non-PA patients are shown in **Table**179 **3**. This analysis was fully adjusted for clinical factors, including potential causal
180 factors for sleep apnea, i.e., age, male gender, BMI, systolic BP, HbA1c, and

renal function. PA was shown to have a significant association with only severe OSA. These results suggest that patients with PA are more likely than hypertensive patients without PA to be complicated by severe sleep apnea under adjustment of the potential causal factors for sleep apnea.

Effects of elevated renin activity on change of sleep apnea

Renin activity and AHI were reevaluated after a mean of 2.5 ± 1.6 years in 45 PA patients. Pearson's correlation coefficient were used to evaluate the association between the logarithm of the renin activity at reevaluation and amount of change in AHI, as shown in **Figure 2**. This relationship was significantly negatively correlated (r = -0.364, p = 0.014).

Discussion

This is the first study to assess cross-sectional associations among PA patients with various degrees of OSA. Moreover, the effects of remaining suppressed renin activity on sleep apnea in patients with PA were prospectively examined. PA was found to be strongly associated with severe sleep apnea under adjustment of the potential causal factors for sleep apnea. Additionally, they

show that elevated renin activity can potentially prevent the progression of sleep apnea in patients with PA.

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

Epidemiological studies have found that PA is a disease that can cause sleep apnea. Among patients with resistant hypertension, the degree of OSA has been reported to be higher in those with hyperaldosteronism ¹⁴. The present results show an association of PA with severe sleep apnea under adjustment of the potential causal factors for sleep apnea. Previously, it was suggested that excessive aldosterone secretion causes inappropriate sodium and fluid retention ⁶. Furthermore, mechanisms related to fluid movement from the lower extremities to the neck caused by edema of the upper airway may contribute to the etiology of OSA 15. Another study noted that patients with OSA who underwent diuretic treatment showed significantly improved upper airway caliber and OSA, further implicating pharyngeal edema as a cause of upper airway collapse during sleep 16. Moreover, a volumetric analysis technique used with magnetic resonance imaging demonstrated that volume of the tongue and lateral walls were independent factors related to increased risk of OSA 17. Impairment of ventilatory-control mechanisms can also contribute to modulation of pharyngeal

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

collapsibility during sleep, thus suggesting a role for central nervous system input, which may be influenced by humoral factors 18-20. Furthermore, basic research results have indicated that aldosterone has a central role in increased brain renin-angiotensin activity, oxidative stress, and sympathetic drive ²¹. Therefore, in addition to pharyngeal edema caused by inappropriate sodium and fluid retention related to hyperaldosteronism, disruptions in normal central respiratory mechanisms by aldosterone-induced activation of central receptors may potentially contribute to the association between PA and sleep apnea severity. Aldosterone receptor antagonists are used as therapeutic agents in patients with PA. Such medication has also been indicated as effective for not only improving hypertension but also preventing complications, including cardiovascular events. Spironolactone treatment for patients with resistant hypertension has been reported to significantly decrease AHI level ²². As for pharmacological treatment for PA, elevated renin activity has been shown useful to prevent development of cardiovascular events, cardiovascular death, and renal dysfunction, thus elevated renin activity is considered to be a therapeutic goal. A possible

mechanism underlying the association between elevated renin activity and sleep apnea following therapeutic intervention may be inhibition of mineralocorticoid receptor activation by aldosterone antagonists or an adrenalectomy for aldosterone-producing adenoma treatment ²³. Elevated renin activity is used as an indicator of suppressed mineralocorticoid receptor activation. Results of the present study indicate that elevated renin activity leads to prevent progress of sleep apnea.

This study has several limitations. First, the findings may not be generalizable to all patients with different blood pressure status. Second, the present cohort did not take into account the effect of change in body weight, as that was not possible to track. Nevertheless, the present findings are considered to provide important initial information for clarification of the association of PA with sleep apnea. Moreover, there was a significant negative correlation between the renin activity after treatment and change in AHI before and after treatment. The results suggest that the increase in renin activity reflects suppression of aldosterone action, which may lead to improvement of sleep apnea via improvement of pharyngeal edema.

Conclusion

As compared to hypertensive patients without PA, patients with PA are more likely to have severe sleep apnea. Furthermore, elevated renin activity may contribute to improvement of sleep apnea in patients with PA.

Perspectives

PA appears to play a fundamental role in development of sleep apnea. The elevated renin activity is used as an indicator of the effects of PA treatment goals as well as need for prevention of various complications. The present study investigated the association of PA with degree of OSA as compared to non-PA patients with hypertension and is the first to report a relationship between elevated renin activity and changes in sleep apnea in PA patients. The results provide important initial insight regarding the association of PA with degree of sleep apnea as well as for determining whether elevated renin activity has effects on sleep apnea in patients with PA.

Acknowledgements

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

The authors are grateful for the excellent technical assistance provided by Tomoe Ushitani and Ai Matsumoto. We also wish to thank the other investigators and staff members, as well as the participants of the HSCAA study for their valuable contributions. **Funding** JSPS KAKENHI grants (24K19043 to Y. Kidawara, 20K18944 to A. Mrimoto) and Hyogo Medical University (Hyogo Innovative Challenge to H. Koyama) were received. **Disclosures** There no conflicts of interest or commercial affiliations to disclose. **Data Availability** The datasets generated during and/or analyzed for the current study are not publicly available, though can be provided by the corresponding author upon reasonable request.

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

10.1016/j.jacc.2005.01.015

Novelty and Relevance What is new? This study sheds light on the currently incompletely understood association between PA and degree of OSA in hypertensive patients and effect of elevated renin activity for change in sleep apnea in patients with PA. An increased risk of severe OSA is revealed in patients with PA. Furthermore, it indicated that elevated renin activity following treatment can possible to prevent sleep apnea progression. What Is Relevant? Our results provide important initial findings to unveil the pathophysiological factors for PA and OSA. Clinical/Pathophysiological Implications? PA is an important risk factor for severe OSA in hypertensive patients, and elevated renin activity following treatment is negatively correlated with progression of sleep apnea. These knowledge could improve the prediction and progression of sleep apnea in patients with PA. References Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence 1. for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243-1248. doi:

311 2. Takeda R, Matsubara T, Miyamori I, Hatakeyama H, Morise T. Vascular 312 complications in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension. The Research Committee 313 314 of Disorders of Adrenal Hormones in Japan. J Endocrinol Invest. 315 1995;18:370-373. doi: 10.1007/BF03347840 316 Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, Sechi 3. 317 LA. Cardiovascular outcomes in patients with primary aldosteronism after 318 treatment. Arch Intern Med. 2008;168:80-85. doi: 319 10.1001/archinternmed.2007.33 320 Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications 4. associated with primary aldosteronism: a controlled cross-sectional study. 321 322 Hypertension. 2013;62:331-336. doi: 323 10.1161/HYPERTENSIONAHA.113.01060 324 5. Shah NA, Yaggi HK, Concato J, Mohsenin V. Obstructive sleep apnea as a risk factor for coronary events or cardiovascular death. Sleep Breath. 325 326 2010;14:131-136. doi: 10.1007/s11325-009-0298-7 327 6. Somers VK, White DP, Amin R, Abraham WT, Costa F, Culebras A, Daniels S, Floras JS, Hunt CE, Olson LJ, et al. Sleep apnea and 328

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

9.

7.

8.

cardiovascular disease: an American Heart Association/american College Of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council On Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). Circulation. 2008;118:1080-1111. doi: 10.1161/CIRCULATIONAHA.107.189375 Wang X, Ouyang Y, Wang Z, Zhao G, Liu L, Bi Y. Obstructive sleep apnea cardiovascular disease and all-cause risk of mortality: meta-analysis prospective cohort studies. Int Cardiol. of 2013;169:207-214. doi: 10.1016/j.ijcard.2013.08.088 Florczak E, Prejbisz A, Szwench-Pietrasz E, Sliwiński P, Bieleń P, Klisiewicz A, Michałowska I, Warchoł E, Januszewicz M, Kała M, et al. Clinical characteristics of patients with resistant hypertension: the RESIST-POL J Hum Hypertens. study. 2013;27:678-685. doi: 10.1038/jhh.2013.32 Preibisz A, Florczak E, Klisiewicz A, Dobrowolski P, Janaszek-Sitkowska

347 H. Bieleń P. Szwench-Pietrasz E. Warchoł-Celińska E. 348 Kołodziejczyk-Kruk S, Janas J, et al. Relationship between primary aldosteronism and obstructive sleep apnoea, metabolic abnormalities and 349 350 cardiac structure in patients with resistant hypertension. Endokrynol Pol. 351 2013;64:363-367. doi: 10.5603/EP.2013.0019 352 Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. 10. 353 Cardiometabolic outcomes and mortality in medically treated primary 354 aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 355 2018;6:51-59. doi: 10.1016/S2213-8587(17)30367-4 356 11. Naruse M, Katabami T, Shibata H, Sone M, Takahashi K, Tanabe A, Izawa S. Ichijo T. Otsuki M. Omura M. et al. Japan Endocrine Society clinical 357 358 practice guideline for the diagnosis and management of primary 359 aldosteronism 2021. J. 2022;69:327-359. Endocr doi: 360 10.1507/endocrj.EJ21-0508 Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, Horio T, 361 12. 362 Hoshide S, Ikeda S, Ishimitsu T, et al. The Japanese Society of 363 Hypertension Guidelines for the Management of Hypertension (JSH 364 2019). **Hypertens** 2019;42:1235-1481. doi:

Res.

365 10.1038/s41440-019-0284-9 366 13. Kapur VK, Auckley DH, Chowdhuri S, Kuhlmann DC, Mehra R, Ramar K, Harrod CG. Clinical Practice Guideline for Diagnostic Testing for Adult 367 Obstructive Sleep Apnea: An American Academy of Sleep Medicine 368 Clinical Practice Guideline. J Clin Sleep Med. 2017;13:479-504. doi: 369 370 10.5664/jcsm.6506 371 14. Gonzaga CC, Gaddam KK, Ahmed MI, Pimenta E, Thomas SJ, Harding SM, Oparil S, Cofield SS, Calhoun DA. Severity of obstructive sleep 372 373 apnea is related to aldosterone status in subjects with resistant 374 hypertension. J Clin Sleep Med. 2010;6:363-368. 375 Shiota S, Ryan CM, Chiu KL, Ruttanaumpawan P, Haight J, Arzt M, 15. JS, Chan C, Bradley TD. Alterations in upper 376 377 cross-sectional area in response to lower body positive pressure in 378 healthy subjects. Thorax. 2007;62:868-872. doi: 10.1136/thx.2006.071183 379 380 16. Bucca CB, Brussino L, Battisti A, Mutani R, Rolla G, Mangiardi L, Cicolin 381 A. Diuretics in obstructive sleep apnea with diastolic heart failure. Chest.

2007;132:440-446. doi: 10.1378/chest.07-0311

382

383 17. Schwab RJ, Pasirstein M, Pierson R, Mackley A, Hachadoorian R, Arens 384 R, Maislin G, Pack Al. Identification of upper airway anatomic risk factors for obstructive sleep apnea with volumetric magnetic resonance imaging. 385 386 Am Respir Crit Care Med. 2003;168:522-530. doi: 10.1164/rccm.200208-866OC 387 Wolk R, Johnson BD, Somers VK. Leptin and the ventilatory response to 388 18. 389 exercise in heart failure. J Am Coll Cardiol. 2003;42:1644-1649. doi: 390 10.1016/j.jacc.2003.06.007 391 19. Somers VK, Mark AL, Zavala DC, Abboud FM. Influence of ventilation and hypocapnia on sympathetic nerve responses to hypoxia in normal 392 393 humans. J Physiol (1985).1989;67:2095-2100. doi: Appl 10.1152/jappl.1989.67.5.2095 394 Somers VK, Mark AL, Zavala DC, Abboud FM. Contrasting effects of 395 20. 396 hypoxia and hypercapnia on ventilation and sympathetic activity in 397 humans. Appl **Physiol** (1985).1989;67:2101-2106. doi: 398 10.1152/jappl.1989.67.5.2101 399 21. Zhang ZH, Yu Y, Kang YM, Wei SG, Felder RB. Aldosterone acts centrally

to increase brain renin-angiotensin system activity and oxidative stress in

400

401 normal rats. Am J Physiol Heart Circ Physiol. 2008;294:H1067-1074. doi: 402 10.1152/ajpheart.01131.2007 403 Yang L, Zhang H, Cai M, Zou Y, Jiang X, Song L, Liang E, Bian J, Wu H, 22. 404 Hui R. Effect of spironolactone on patients with resistant hypertension and obstructive sleep apnea. Clin Exp Hypertens. 2016;38:464-468. doi: 405 10.3109/10641963.2015.1131290 406 407 23. Valaiyapathi B, Calhoun DA. Role of Mineralocorticoid Receptors in Obstructive Sleep Apnea and Metabolic Syndrome. Curr Hypertens Rep. 408 409 2018;20:23. doi: 10.1007/s11906-018-0819-5 410 411 Figure legends 412 Figure 1. Flow of subject selection. 413 414 eGFR, estimated glomerular filtration rate; PA, primary aldosteronis. 415 Figure 2. Association between renin activity following treatment and 416 417 amount of changes in AHI. 418 Correlation coefficient and p values for association between renin activity following treatment and amount of change in AHI were calculated using a 419

Pearson's correlation coefficient.

420

421

Table 1. Comparisons of baseline clinical characteristics

Variables	PA	Non-PA	Р	
Number of patients	176	418		
Age, years	57.1 ± 12.8	63.7 ± 12.2	< 0.001	
Male, n (%)	84 (47.7)	231 (55.3)	0.112	
Body mass index, kg/m ²	25.4 ± 4.9	25.3 ± 5.2	0.682	
Current smoker, n (%)	41 (23.3)	113 (27.0)	0.397	
Systolic BP, mmHg	137.2 ± 15.7	131.2 ± 14.4	< 0.001	
Diastolic BP, mmHg	82.4 ± 10.3	76.4 ± 9.0	< 0.001	
LDL cholesterol, mg/dL	112.6 ± 29.4	111.8 ± 32.5	0.818	
HDL cholesterol, mg/dL	54.8 ± 15.9	53.1 ± 17.0	0.273	
Triacylglycerol, mg/dL	120.5 (84.0 – 165.3)	115.0 (85.0 – 171.0)	0.911	
eGFR, mL/min/1.73 m ²	80.0 ± 19.2	77.6 ± 23.0	0.224	
Fasting plasma glucose, mg/dL	98 (91 - 106)	101 (93 - 121)	<0.001	
HbA1c (%)	5.5 (5.2 - 5.9)	5.9 (5.3 - 6.8)	<0.001	
Plasma renin activity, ng/mL/hour	0.4 (0.2 - 0.6)	0.9 (0.5 - 2.1)	<0.001	
Plasma aldosterone concentration, pg/mL	212.5 (153.0 – 293.8)	102.0 (63.6 – 150.0)	<0.001	
Comorbidities				
Diabetes, n (%)	29 (16.5)	197 (47.1)	<0.001	
Dyslipidemia, n (%)	99 (56.3)	284 (67.9)	0.009	
Anti-hypertensive drugs				
Calcium channel blocker, n (%)	108 (71.5)	262 (68.8)	0.604	
α blocker, n (%)	12 (7.9)	31 (8.1)	1.000	

Diuretic agent, n (%)	18 (11.9)	34 (8.9)	0.375
Sleep apnea			
AHI, n (%)	10.0 (4.8-20.3)	9.7 (3.9-19.6)	0.281
Normal (<5), n (%)	47 (26.7)	125 (29.9)	0.493
Mild (5 to <15), n (%)	68 (38.6)	145 (34.7)	0.411
Moderate (15 to <30), n (%)	33 (18.8)	104 (24.9)	0.130
Severe (AHI ≥30), n (%)	28 (15.9)	44 (10.5)	0.090

Data are presented as the mean ± standard deviation or median (25th-75th percentile) for continuous variables or number (%) for categorical dichotomous variables. P values based on the two-sample Welch's t-test or Mann-Whitney U-test are shown for comparisons of location parameters, such as the mean or median of two groups, or P values based on the Fisher's exact test for comparisons of percentage between groups. PA, primary aldosteronism; BP, blood pressure; LDL, low density lipoprotein; HDL, high density lipoprotein; eGFR, estimated glomerular filtration rate; AHI, apnea-hypopnea index

Table 2. Comparisons of baseline clinical characteristics among subjects divided based on degree of sleep apnea

Variables	Normal (AHI <5)	Mild (AHI 5 to <15)	Moderate (AHI 15 to <30)	Severe (AHI ≥30)	P value (Normal vs. Mild)	P value (Normal vs. Moderate)	P value (Normal vs. Severe)
Number	170	214	138	72	-	-	-
Age, years	59.3 ± 14.0	62.2 ± 11.7	64.9 ± 11.4	60.6 ± 13.8	0.026	<0.001	0.489
Male, n (%)	74 (43.5)	117 (54.7)	81 (58.7)	43 (59.7)	0.039	0.011	0.031
Body mass index, kg/m ²	22.9 ± 3.6	25.1 ± 4.7	26.1 ± 4.8	30.1 ± 6.4	<0.001	<0.001	<0.001
Current smoker, n (%)	37 (21.8)	59 (27.6)	34 (24.6)	24 (33.3)	0.235	0.646	0.083
Systolic BP, mmHg	130.2 ± 14.5	133.6 ± 15.3	133.6 ± 15.3	136.4 ± 14.3	0.024	0.045	0.002
Diastolic BP, mmHg	77.6 ± 10.1	78.9 ± 9.6	77.6 ± 9.5	78.7 ± 10.2	0.221	0.990	0.458
LDL cholesterol, mg/dL	112.8 ± 33.4	110.0 ± 31.5	113.2 ± 28.8	114.2 ± 32.5	0.540	0.930	0.798
HDL cholesterol, mg/dL	55.5 ± 18.0	54.9 ± 16.0	51.0 ± 15.1	50.3 ± 17.3	0.709	0.021	0.039
Triacylglycerol, mg/dL	102 (78 - 147)	115 (84 - 154)	125 (96 - 179)	141 (106 - 194)	0.203	0.002	<0.001
eGFR, mL/min/1.73m ²	83.0 ± 21.9	78.5 ± 21.8	75.6 ± 20.4	72.1 ± 23.6	0.043	0.002	<0.001
Fasting plasma glucose, mg/dL	97 (90 - 105)	101 (93 - 116)	104 (94 - 126)	103 (95 - 118)	0.001	<0.001	< 0.001
HbA1c (%)	5.4 (5.1 - 6.0)	5.7 (5.3 - 6.6)	5.9 (5.4 - 6.8)	6.0 (5.6 - 6.8)	<0.001	< 0.001	< 0.001
Plasma renin activity, ng/mL/hr	0.7 (0.4 - 1.6)	0.6 (0.3 - 1.2)	0.8 (0.4 - 2.1)	0.8 (0.4 -1.7)	0.234	0.222	0.595
Plasma aldosterone concentration, pg/mL	127 (74 - 198)	121 (78 - 187)	125 (80 - 195)	147 (74 - 215)	0.812	0.662	0.718
Comorbidities							
Diabetes, n (%)	47 (27.6)	84 (39.3)	62 (44.9)	33 (45.8)	0.023	0.002	0.009


Dyslipidemia, n (%)	97 (57.1)	134 (62.6)	96 (70.0)	56 (77.8)	0.317	0.033	0.004
Anti-hypertensive drugs							
Calcium-channel blocker, n (%)	104 (68.9)	129 (67.2)	85 (69.1)	52 (78.8)	0.829	1.000	0.183
α blocker, n (%)	10 (6.6)	14 (7.3)	8 (6.5)	11 (16.7)	0.978	1.000	0.040
Diuretic agent, n (%)	8 (5.3)	23 (12.0)	14 (11.4)	7 (10.6)	0.051	0.105	0.260
Sleep apnea							
AHI	2.4 (1.1 - 3.6)	9.0 (7.1 - 11.5)	20.1 (16.7 - 24.2)	39.9 (33.0 - 45.6)	< 0.001	< 0.001	< 0.001
PA, n (%)	45 (26.5)	69 (32.2)	34 (24.6)	28 (38.9)	0.264	0.814	0.077

Data are presented as the mean ± standard deviation or median (25th-75th percentile) for continuous variables, or number (%) for categorical variables. P values based on the two-sample Welch's t-test or Mann-Whitney U-test are shown for comparisons of location parameters, such as mean or median of two groups, or P values based on the Fisher's exact test for comparisons of percentage between groups. PA, primary aldosteronism; EH, essential hypertension; AHI, apnea-hypopnea Index; BP, blood pressure; LDL, low density lipoprotein; HDL, high density lipoprotein; eGFR, estimated glomerular filtration rate


Table 3. Multivariable logistic regression analysis of factors associated with degree of sleep apnea

	Mild (AHI 5 to <15)		Moderate (AHI 15	to <30)	Severe (AHI ≥30)		
Variables	OR (95%CI)	Р	OR (95%CI)	Р	OR (95%CI)	Р	
Age, years (per 5)	1.02 (0.95 - 1.11)	0.560	1.18 (1.07 - 1.30)	0.001	1.13 (1.00 - 1.05)	0.084	
Male	1.16 (0.82 - 1.63)	0.410	1.29 (0.87 - 1.91)	0.212	1.56 (0.88 - 2.78)	0.130	
Body mass index, kg/m ² (per 5)	0.94 (0.78 - 1.13)	0.492	1.35 (1.1 - 1.65)	0.004	2.78 (2.08 – 3.73)	<0.001	
Systolic BP, mmHg (per 10)	1.03 (0.92 - 1.16)	0.615	1.04 (0.91 - 1.19)	0.566	1.11 (0.92 – 1.34)	0.275	
HbA1c (%)	1.05 (0.92 - 1.20)	0.485	1.08 (0.93 - 1.25)	0.335	1.16 (0.94 - 1.43)	0.174	
eGFR, mL/min/1.73 m ² (per 5)	1.00 (0.97 - 1.05)	0.708	1.00 (0.95 - 1.05)	0.897	0.93 (0.86 – 1.00)	0.045	
PA (vs. non-PA)	1.28 (0.86 - 1.90)	0.229	0.97 (0.60 - 1.57)	0.905	2.08 (1.09 – 3.95)	0.025	

PA, primary aldosteronism; BP, blood pressure; eGFR, estimated glomerular filtration rate; OR, odds ratio; CI, confidence interval



Final analysis including subjects with PA re-evaluated for sleep apnea and renin activity (total = 45)



● ΔAHI(post-pre), amount of change — 95% prediction ellipse